U.S.: Sight Sciences to Debut OMNI® Edge Surgical System at 2025 ASCRS Annual Meeting

Sight Sciences, Inc. (Nasdaq: SGHT) , an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, announced the expansion of the OMNI^® product family by launching the OMNI^® Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, taking place April 25–27 in Los Angeles, California.

OMNI Edge with TruSync™ technology builds on the proven performance of the OMNI^® Surgical System and introduces a higher-capacity viscoelastic delivery feature (21 µL) while maintaining the trusted safety, efficacy, and usability of the OMNI device. Designed for versatility in minimally invasive glaucoma surgery (MIGS), OMNI Edge reduces intraocular pressure (IOP) by treating all three known areas of resistance in the aqueous outflow system—the trabecular meshwork, Schlemm’s canal, and the collector channels. The system is adaptable to all stages of primary open-angle glaucoma (POAG) and can be used as a standalone procedure or in combination with cataract surgery.

"OMNI Edge represents the next step in providing the most comprehensive and versatile implant-free MIGS technology. The higher viscoelastic capacity, ergonomics, and predictability enhance my ability to safely and comprehensively treat a wide range of primary open-angle glaucoma cases,” said Christine Funke, MD, following early clinical use.

Key features of OMNI Edge:

• TruSync technology: A patented viscoelastic delivery technology synchronized with surgeon rotation of the control wheel — enabling consistent, predictable, and reproducible viscoelastic deployment along every clock hour of Schlemm’s canal that is treated.
• Expanded viscoelastic capacity: Delivers up to 21 µL—nearly double the 11 µL capacity of the OMNI Surgical System — with precise control, while maintaining the trusted ergonomics, safety, and versatility of the OMNI Surgical System.
• Trusted ergonomics: Retains the intuitive design of the OMNI Surgical System, preserving the intuitive handling surgeons know and trust, enabling a seamless adoption.

"Sight Sciences remains dedicated to evolving glaucoma care with interventional technologies that align with the way surgeons treat their patients safely, efficiently, and comprehensively," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "OMNI Edge is a testament to our commitment to innovation and ongoing collaboration with the ophthalmic community."

Multiple studies, including prospective, long-term, and real-world have demonstrated the safety, effectiveness, and durability of the OMNI procedure in both standalone and combination cataract procedures. With over 300,000 procedures performed,¹ OMNI has established itself as a leader in canal-based MIGS.

The introduction of OMNI Edge expands the OMNI product family while maintaining the availability of OMNI, ensuring surgeons have access to both technologies to meet their unique surgical preferences and patient needs. OMNI Edge is only available in the United States.